GALVmed aims to make a significant contribution towards transformational change in the small-scale livestock health landscape by developing a portfolio of high impact products and initiating a range of private sector market initiatives operating at scale in the smallholder sector.
About usTransformational improvement in the well-being and economic progression of small-scale livestock producers.
We will contribute to the transformation of small-scale livestock producers’ lives by:
Product development
GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.
Commercial development
Our work with our partners supports the small-scale livestock producers of the world.
Enabling Environment
An enabling environment that allows for the successful translation of research products to sustainable animal health solutions for small scale livestock producers is essential to achieving GALVmed’s mission.
2022-09-26
Timely and effective marketing authorisation of veterinary medicines requires a combination of rigorous scientific evaluation and efficient management of procedures. In line with GALVmed’s role in implementing the AgResults Foot and Mouth Disease (FMD) Vaccine …
Small livestock are a pathway out of poverty and source of economic and gender empowerment, and yet, for millions of small-scale producers, these very important assets are threatened by diseases.
Goats, sheep, pigs, chickens. These are some of the small livestock that are giving millions of people opportunities.
Small livestock are a pathway out of poverty and source of economic and gender empowerment, and yet, for millions of small-scale producers, these very important assets are threatened by diseases.
Goats, sheep, pigs, chickens. These are some of the small livestock that are giving millions of people opportunities.
Obtaining approval to sell veterinary medicines in the market requires a marketing authorisation (licence) from the National Regulatory Authority in each country where the product is to be sold.
In 2020, Oxford Policy Management (OPM) was contracted by GALVmed to implement an intervention and conduct an associated impact study on the adoption of a Newcastle Disease Vaccine (NDV) by small-scale poultry farmers in rural Tanzania in the districts of Chemba and Mbozi.
